According to a study by the World Health Organization (WHO), cancer is the cause for every one death out of six occurrences. Growing cases of cancers such as breast cancer, lung cancer and others due to poor diet patterns, air pollution, sexually transmitted infections, alcohol consumption. Other types of cancer are liver cancer, pancreas cancer, brain cancer, bladder cancer, colon, and blood cancer. The most common cures for cancer are chemotherapy, radiation, and surgeries. These procedures have an adverse effect on the human body. High doses of radiation and chemotherapy destroy the blood-forming stem cells. Stem cells are the soft tissues of the bone that grow inside the bone marrow. Stem cell transplants restore the blood-forming stem cells. These stem cells grow into platelets, RBCs, and WBCs that are required by the body to fight illness and provide oxygen. Usually, these transplants are done within the family to find the closest match.
Stem Cells for Cancer
Cancer stem cells or CSCs are a subpopulation of cells that has the driving force of carcinogenesis. Characteristics of cancer stem cells are proliferation, and differentiation capabilities and distinctive self-renewal. These characteristics play a vital role in many stages of cancer such as cancer initiation, drug resistance, progression, maintenance, and metastasis or relapse. CSCs have traits that are linked with normal stem cells and are found within hematological cancers or tumors.
Stem Cell-based therapy
According to the World Health Organization (WHO), the most common cause of deaths in women diagnosed with cancer is breast cancer. Global cancer stem cells market is projected to reach up to $896.9 million by the end of 2026 as the stem cell-based cancer therapy and targeted cancerous stem cell therapy are advancing in the medical field. Cell-based therapy is split into allogenic Stem Cell therapy and autologous Stem Cell therapy. Allogenic Hematopoietic Stem Cell Transplantation is more beneficial than the autologous Hematopoietic Stem Cell Transplantation for Breast cancer based on different aspects such as cancer-free graft & immune-mediated Graft vs Tumor effect mediated by the donor’s immune cell.
Successful engraftment rates together with lesser transplant-related mortality and the presence of Graft vs Tumor effect made allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity conditioning is the better choice option for the treatment of multiple solid tumors. Due to aforesaid aspects, it is anticipated that allogenic cell therapy will be the rising point for the cancer stem cell market. The global market for stem cell-based cancer therapy is estimated to grow at 9.3% CAGR in 2026 from $440.3 million in 2018.
Advancements in Cancer Stem Cell Transplantation
The prime reason for such huge growth is majorly owed to the rising developments in stem cell therapy of the Asia-Pacific and Europe region. Physicians in Canada are endorsing and promotion of stem cell interventions, which are ethical, legal, and regulatory. U.S. and Canada are leading the cancer stem cell market in the North America region. The North America market is expected to grow over the forecast period and is further projected to generate revenue of $783.8 million by 2026 from its market value of $365.6 million in 2018. While the Asia-Pacific Cancer Stem Cells Market is anticipated to rise to $367.7 Million till 2026 and the Europe Cancer Stem Cells Market is anticipated to generate revenue of $419.5 Million till 2026. Amongst these regions, the Asia-Pacific region is anticipated to be the fastest-growing region for cancer stem cells market. Governing bodies of India, Japan, and other countries are promoting Stem cell transplant by constructing new infrastructure and enlisting new strategies for the launch of centers of stem cells.
The major players in the global cancer stem cell market are introducing several strategies to reinforce their presence in the market
Some of these strategies are introducing new product development and merger & acquisitions. Celula Inc. declared a long term lease agreement In April 2019, for the development of 145,000 square-foot advanced cell manufacturing and research facility in the U.S. Other market players include:
- Advanced Cell Diagnostics Inc.
- Fluxion Biosciences Inc.
- Silicon Biosystems, S.p.A.
- AdnaGen GmbH
- AVIVA Biosciences Corporation
- Epic Sciences Inc.
- Rarecells USA Inc.